BJTJ-00012 is under clinical development by Beijing Tuojie Biomedical Technology and currently in Phase II for Unspecified Metabolic Disorders. According to GlobalData, Phase II drugs for Unspecified Metabolic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BJTJ-00012 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BJTJ-00012 overview

BJTJ-0001-2 is under development for the treatment of unspecified metabolic disease.

Beijing Tuojie Biomedical Technology overview

Beijing Tuojie Biomedical Technology is a biotechnology company that specializes in the research and development of therapeutic proteins, peptide biopharmaceuticals and stem cell drugs for chronic diseases such as metabolic diseases, cardiovascular diseases, nervous system diseases and osteoarthritis. The company is headquartered in Beijing, China.

For a complete picture of BJTJ-00012’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.